Arcellx Skyrockets After Gilead Makes A $7.8 Billion Bet On Its Cancer Drug Partner
Investor's Business Daily • • general
Key Points:
- Investor’s Business Daily (IBD) provides information solely for educational and informational purposes and does not offer investment advice or recommendations.
- The data presented is believed to be reliable but is not guaranteed for accuracy, timeliness, or suitability, and past performance does not predict future results.
- Authors and presenters may hold positions in the stocks they discuss, and IBD makes no warranty regarding the advisability of any investment or strategy.
- Real-time price data is sourced from Nasdaq Last Sale but may not cover all markets, with ownership and estimate data provided by LSEG and FactSet respectively.
- All trademarks mentioned, including IBD and related brands, are owned by Investor’s Business Daily, LLC, which reserves all rights.
